Subtyping of Blastocystis in Urticarial Patients in Turkey

Aim: This study aims to investigate Blastocystis’ etiologic role and association with gastrointestinal symptomatology in acute and chronic urticaria patients and to identify Blastocystis subtypes responsible for urticaria. Method: The study included urticaria patients and healthy individuals referred to the Erzincan University Mengücek Gazi Training and Research Hospital Dermatology Polyclinic between June 2015 and May 2017. Participants were divided into Group I (133 patients), subdivided into acute (70) and chronic urticaria patients (63), and Group II (123 control individuals). Blastocystis presence was investigated by native-lugol examination, trichrome staining, PCR using STS primers, and DNA sequencing analysis. Sequences were aligned using CLUSTALW, and phylogenetic tree was constructed using MEGA version 7.0. Participants completed a questionnaire inquiring age, gender, urticaria existence, drinking-water source, animal raising, itching and gastrointestinal complaints. Results: The native-lugol and trichome staining methods revealed sixteen of 133 patients (12%) had Blastocystis positive stool samples. Seven positive samples (7/70; 10%) belonged to acute and nine (9/63; 14.3%) to chronic urticaria patients. Concerning Blastocystis subtypes, of the acute urticaria patients, three had ST1, one had ST2, and three had ST3. Of the chronic urticaria patients, one had ST1 and eight had ST3. Blastocystis positivity was detected in two control individuals (1.6%), both being ST3. All subtypes identified by PCR were confirmed by sequence analysis. The acute and chronic urticaria groups showed no statistically significant differences for Blastocystis positivity and subtype distribution (p = 0.595, p = 0.149). A statistically significant difference was found between urticaria patients and the control group for Blastocystis positivity but not for subtype distribution (p = 0.001, p = 0.658) or for Blastocystis presence and gender, drinkingwater source, animal raising, gastrointestinal complaints, itching. Conclusion: This is the first study on Blastocystis subtype distribution among Turkish urticaria patients and the results consistent with data from urticaria patient studies.

Erişime Açık
Görüntülenme
3
22.03.2024 tarihinden bu yana
İndirme
1
22.03.2024 tarihinden bu yana
Son Erişim Tarihi
19 Nisan 2024 14:25
Google Kontrol
Tıklayınız
Tam Metin
Tam Metin İndirmek için tıklayın Ön izleme
Detaylı Görünüm
Eser Adı
(dc.title)
Subtyping of Blastocystis in Urticarial Patients in Turkey
Yayın Türü
(dc.type)
Konferans Bildirisi
Yazar/lar
(dc.contributor.author)
AYDIN, Merve
Yazar/lar
(dc.contributor.author)
YAZICI, Mustafa
Yazar/lar
(dc.contributor.author)
DEMİRKAZIK, Mehtap
Yazar/lar
(dc.contributor.author)
KOLTAŞ, İsmail Soner
Yazar/lar
(dc.contributor.author)
ÇIKMAN, Aytekin
Yazar/lar
(dc.contributor.author)
GÜLHAN, Barış
Yazar/lar
(dc.contributor.author)
DURAN, Tuğçe
Yazar/lar
(dc.contributor.author)
YILMAZ, Aysun
Yazar/lar
(dc.contributor.author)
KARA, Murat
Atıf Dizini
(dc.source.database)
Diğer
Konu Başlıkları
(dc.subject)
Blastocystis Sp
Konu Başlıkları
(dc.subject)
DNA Sequence Analysis
Konu Başlıkları
(dc.subject)
PCR
Konu Başlıkları
(dc.subject)
Subtypes
Konu Başlıkları
(dc.subject)
Urticaria
Yayın Tarihi
(dc.date.issued)
2018
Kayıt Giriş Tarihi
(dc.date.accessioned)
2019-07-10T08:17:24Z
Açık Erişim tarihi
(dc.date.available)
2019-07-10T08:17:24Z
Özet
(dc.description.abstract)
Aim: This study aims to investigate Blastocystis’ etiologic role and association with gastrointestinal symptomatology in acute and chronic urticaria patients and to identify Blastocystis subtypes responsible for urticaria. Method: The study included urticaria patients and healthy individuals referred to the Erzincan University Mengücek Gazi Training and Research Hospital Dermatology Polyclinic between June 2015 and May 2017. Participants were divided into Group I (133 patients), subdivided into acute (70) and chronic urticaria patients (63), and Group II (123 control individuals). Blastocystis presence was investigated by native-lugol examination, trichrome staining, PCR using STS primers, and DNA sequencing analysis. Sequences were aligned using CLUSTALW, and phylogenetic tree was constructed using MEGA version 7.0. Participants completed a questionnaire inquiring age, gender, urticaria existence, drinking-water source, animal raising, itching and gastrointestinal complaints. Results: The native-lugol and trichome staining methods revealed sixteen of 133 patients (12%) had Blastocystis positive stool samples. Seven positive samples (7/70; 10%) belonged to acute and nine (9/63; 14.3%) to chronic urticaria patients. Concerning Blastocystis subtypes, of the acute urticaria patients, three had ST1, one had ST2, and three had ST3. Of the chronic urticaria patients, one had ST1 and eight had ST3. Blastocystis positivity was detected in two control individuals (1.6%), both being ST3. All subtypes identified by PCR were confirmed by sequence analysis. The acute and chronic urticaria groups showed no statistically significant differences for Blastocystis positivity and subtype distribution (p = 0.595, p = 0.149). A statistically significant difference was found between urticaria patients and the control group for Blastocystis positivity but not for subtype distribution (p = 0.001, p = 0.658) or for Blastocystis presence and gender, drinkingwater source, animal raising, gastrointestinal complaints, itching. Conclusion: This is the first study on Blastocystis subtype distribution among Turkish urticaria patients and the results consistent with data from urticaria patient studies.
Yayın Dili
(dc.language.iso)
en
Tek Biçim Adres
(dc.identifier.uri)
https://hdl.handle.net/20.500.12498/1041
Analizler
Yayın Görüntülenme
Yayın Görüntülenme
Erişilen ülkeler
Erişilen şehirler
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve cerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms